NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Director Group L. P. Column Purchases 37,639 Shares

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) Director Group L. P. Column bought 37,639 shares of the company’s stock in a transaction on Thursday, January 19th. The shares were bought at an average price of $5.00 per share, for a total transaction of $188,195.00. Following the completion of the acquisition, the director now directly owns 732,559 shares in the company, valued at approximately $3,662,795. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

NGM Biopharmaceuticals Stock Down 1.4 %

Shares of NGM opened at $5.02 on Tuesday. The stock has a market capitalization of $410.26 million, a P/E ratio of -2.57 and a beta of 1.23. NGM Biopharmaceuticals, Inc. has a twelve month low of $2.92 and a twelve month high of $18.25. The company has a 50 day moving average of $5.18 and a 200-day moving average of $10.02.

NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) last released its earnings results on Thursday, November 3rd. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.02. NGM Biopharmaceuticals had a negative net margin of 264.09% and a negative return on equity of 50.12%. The business had revenue of $7.91 million during the quarter, compared to analysts’ expectations of $7.02 million. On average, sell-side analysts anticipate that NGM Biopharmaceuticals, Inc. will post -2.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NGM Biopharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in NGM. Point72 Hong Kong Ltd lifted its holdings in NGM Biopharmaceuticals by 102.8% during the 1st quarter. Point72 Hong Kong Ltd now owns 2,034 shares of the company’s stock valued at $31,000 after purchasing an additional 1,031 shares during the last quarter. Royal Bank of Canada lifted its holdings in NGM Biopharmaceuticals by 353.2% during the 3rd quarter. Royal Bank of Canada now owns 3,195 shares of the company’s stock valued at $41,000 after purchasing an additional 2,490 shares during the last quarter. Amalgamated Bank acquired a new stake in NGM Biopharmaceuticals during the 1st quarter valued at $60,000. Steward Partners Investment Advisory LLC lifted its holdings in NGM Biopharmaceuticals by 138.8% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 4,817 shares of the company’s stock valued at $62,000 after purchasing an additional 2,800 shares during the last quarter. Finally, Diversified Trust Co acquired a new stake in NGM Biopharmaceuticals during the 4th quarter valued at $65,000. 64.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Cowen dropped their target price on shares of NGM Biopharmaceuticals from $32.00 to $9.00 and set an “outperform” rating on the stock in a report on Tuesday, October 18th. Jefferies Financial Group downgraded shares of NGM Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 17th. Cowen dropped their target price on shares of NGM Biopharmaceuticals from $32.00 to $9.00 and set an “outperform” rating on the stock in a report on Tuesday, October 18th. B. Riley dropped their target price on shares of NGM Biopharmaceuticals from $29.00 to $8.00 in a report on Monday, October 17th. Finally, Raymond James cut shares of NGM Biopharmaceuticals from a “strong-buy” rating to an “outperform” rating and decreased their price target for the stock from $42.00 to $4.00 in a research note on Monday, October 17th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About NGM Biopharmaceuticals

(Get Rating)

NGM Biopharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH.